Heart failure & cardiomyopathies
Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme
Authors' conclusion
In patients with HFpEF enrolled across the STEP-HFpEF and STEP-HFpEF DM trials, treatment with semaglutide improved disease-specific symptoms, physical function and reduced body weight across the age spectrum. The safety profile of semaglutide was consistent in older and younger patients.
Study context
- Population
- Obesity-related heart failure with preserved ejection fraction (HFpEF), by age (<55, 55–64, 65–74, ≥75 years)
- Participants
- 573 vs 572
- Comparison
- Semaglutide vs placebo across age groups
- Semaglutiden = 573
- Placebon = 572reference
- Primary endpoint
- Dual primary: change in KCCQ-CSS and change in body weight, across age groups
- Follow-up
- 52 weeks
Methodological detailspre-specified pooled subanalysis
- Pre-specified pooled subanalysis
Primary result
As reported in the abstract
Dual primary endpoints across age groups
- Semaglutide efficacy on KCCQ-CSS consistent across the age spectrum
- p-interaction = 0.80
- Semaglutide efficacy on body weight consistent across the age spectrum
- p-interaction = 0.41
Secondary outcomes
Key secondary endpoints (6MWD, C-reactive protein, hierarchical composite) across age groups
- Similar benefits, no treatment effect heterogeneity across age groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme. Eur J Heart Fail. Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →